Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BASECAMP: SAT-3247 in Ambulatory DMD Patients
NCT07287189Phase 2Active, not recruiting
- Sponsor
- Satellos Bioscience Inc.
- Start
- Dec 2025
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of forazapadin in Duchenne muscular dystrophy (DMD) (3 arms), sponsored by Satellos Bioscience Inc. Primary endpoints: Safety of SAT-3247 at 12 months, Tolerability of SAT-3247 at 12 months and 1 more. Started Dec 2025; status: active, not recruiting.
02
Drugs
forazapadin
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT07287189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07287189.